TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11458721

Group type: EXPERIMENTAL
Intervention: Urapidil (25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (5 ml isotonic saline)
Number of subjects: 20
Study: 9916608

Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 2 hours before sparfloxacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 2 hours after sparfloxacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maalox 30 mL given 4 hours after sparfloxacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sparfloxacin alone
Number of subjects: 20
Study: 7994500

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Analytic psychotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Anxiety management training
Number of subjects: 110
Study: 2914634

Group type: EXPERIMENTAL
Intervention: HCl solutions (pH 1, 1.5, 2, 2.5, 3, 4, 5, and 6) infused at 8 ml/min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 24-h pH monitoring
Number of subjects: 25
Study: 9648

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 58

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 58
Study: 30021245

Group type: EXPERIMENTAL
Intervention: Uroflowmetry-based predictive model
Number of subjects: 300
Study: 26996270

Group type: EXPERIMENTAL
Intervention: Disclosure to romantic partners
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Disclosure to close friends
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Disclosure to casual friends
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Disclosure to bosses
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Disclosure to co‐workers
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher social support
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher social functioning
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher medication adherence self‐efficacy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lower lung-function
Number of subjects: 128
Study: 25711319

Group type: EXPERIMENTAL
Intervention: START trial intervention (specific details not provided)
Number of subjects: 4688
Study: 23970193

Group type: EXPERIMENTAL
Intervention: Early active mobilization following Mitek bone anchor repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative rehabilitation involving thumb spica immobilization
Number of subjects: 0
Study: 20943065

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18378872

Group type: EXPERIMENTAL
Intervention: GSM exposure
Number of subjects: 496

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 496
Study: 16996831

Group type: EXPERIMENTAL
Intervention: Early ED eptifibatide
Number of subjects: 343

Group type: COMPARATOR
Intervention: CCL eptifibatide
Number of subjects: 343
Study: 14986738

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cyclosporin ME
Number of subjects: 179
Study: 11225291

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Dust levels in classrooms
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Cleaning frequency of desks
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Wet mopping
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PVC floor material
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure
Number of subjects: 234
Study: 8956397

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needles (CSF not identified, local anesthetic not injected)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre spinal needles (CSF not identified, local anesthetic not injected)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needles (CSF identified, local anesthetic injected)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre spinal needles (CSF identified, local anesthetic injected)
Number of subjects: 32
Study: 1532445

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg, days 1-21) + Medroxyprogesterone acetate (10 mg, days 12-21)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (1.5 mg, days 1-24) + Desogestrel (150 micrograms, days 13-24)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All hormone-treated groups
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Secretory phase
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Serum placental protein 14
Number of subjects: 56
Study: 3925217

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 240 mg daily (6 X 40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 10
Study: 30251943

Group type: EXPERIMENTAL
Intervention: Intraoperative antithymocyte globulin infusion via coronary sinus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional antithymocyte globulin infusion after implantation
Number of subjects: 30
Study: 30908373

Group type: EXPERIMENTAL
Intervention: ALC + SDP
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLA + SLE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ALC + SLE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PLA + SDP
Number of subjects: 10
Study: 29111960

Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated aspirin daily
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 27368439

Group type: EXPERIMENTAL
Intervention: Pranlukast (leukotriene antagonist) administered for up to 28 days along with antibiotics.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group received antibiotic-based conventional treatment according to guidelines.
Number of subjects: 97
Study: 24568906

Group type: EXPERIMENTAL
Intervention: Huangqi injection (0.5-1.0 mL/kg per day) by intravenous infusion
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection (control)
Number of subjects: 105
Study: 23941474

Group type: EXPERIMENTAL
Intervention: Lithium added to current therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy without lithium
Number of subjects: 0
Study: 20086263

Group type: EXPERIMENTAL
Intervention: Internet training aid (MyMigraine) for migraine self-management
Number of subjects: 16
Study: 18239180

Group type: EXPERIMENTAL
Intervention: rFVIIa (5 to 160 microg/kg)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: rFVIIa (120 to 160 microg/kg)
Number of subjects: 486
Study: 16174073

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (combined interferon (IFN; 3 or 5 million units of IFN alpha‐2b thrice weekly) plus ribavirin (1000‐1200 mg per day) for 24‐48 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (40 age- and sex-matched patients with similar characteristics of tumors and severity of liver disease)
Number of subjects: 60
Study: 12787989

Group type: EXPERIMENTAL
Intervention: Children under altered sensory environments (open eye, closed eye, sway-referenced vision) with fixed foot support and compliant foot support
Number of subjects: 34

Group type: COMPARATOR
Intervention: Young adults under altered sensory environments (open eye, closed eye, sway-referenced vision) with fixed foot support and compliant foot support
Number of subjects: 34
Study: 10691226

Group type: COMPARATOR
Intervention: Plasma control TCI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Effect-site control TCI (Group II) with t1/2k(eo) of 3.5 min
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Effect-site control TCI (Group III) with k(eo) yielding a time to peak effect of 1.6 min
Number of subjects: 120
Study: 8851377

Group type: EXPERIMENTAL
Intervention: 10 micrograms.kg‐1 intrathecal morphine (Group A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 20 micrograms.kg‐1 intrathecal morphine (Group B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 30 micrograms.kg‐1 intrathecal morphine (Group C)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study: 1626757

Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler (0.5 mg qid)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Albuterol chlorofluorocarbon (CFC) inhaler (0.2 mg qid)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Preference for terbutaline Turbuhaler
Number of subjects: 85

Group type: COMPARATOR
Intervention: Preference for albuterol CFC inhaler
Number of subjects: 85
Study: 3780408

Group type: EXPERIMENTAL
Intervention: Mental rehearsal before drinking (MRBD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mental rehearsal after drinking (MRAD)
Number of subjects: 12
Study: 31305232

Group type: EXPERIMENTAL
Intervention: Behavioral medicine treatment (BMT)
Number of subjects: 3
Study: 29462823

Group type: EXPERIMENTAL
Intervention: Trauma-focused counseling
Number of subjects: 190

Group type: COMPARATOR
Intervention: Stress counseling (active control)
Number of subjects: 190
Study: 27916372

Group type: EXPERIMENTAL
Intervention: TissueLink
Number of subjects: 67

Group type: COMPARATOR
Intervention: SEAMGUARD
Number of subjects: 67
Study: 24731671

Group type: EXPERIMENTAL
Intervention: 50 μg eprotirome
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 100 μg eprotirome
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 20491818

Group type: EXPERIMENTAL
Intervention: Early implant placement (healing sites)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional implant placement (healed sites)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both early and conventional implant placements
Number of subjects: 49
Study: 19168315

Group type: EXPERIMENTAL
Intervention: Pre-prandial scans (fasting state)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-prandial scans (non-fasting state)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-prandial gallbladder area
Number of subjects: 46

Group type: COMPARATOR
Intervention: Total time to scan for fasting volunteers
Number of subjects: 46
Study: 18562772

Group type: EXPERIMENTAL
Intervention: Carbohydrate gel (0.24 g/kg body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10
Study: 15726094

Group type: EXPERIMENTAL
Intervention: Home exercise instruction
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Strength estimates obtained by use of a Nicholas electronic dynamometer and range of motion in the standing position
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI) and the University of Pennsylvania (UPenn) Shoulder Scale
Number of subjects: 108
Study: 12799094

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily for 2 weeks, increased to 80 mg if BP remained >/=130/85 mm Hg)
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Telmisartan (titration from 40 mg to 80 mg)
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 2705
Study: 10438995

Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Recombinant FSH
Number of subjects: 51
Study: 8571075

Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of ethanol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of methanol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of acetone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control specimens analyzed between 1987 and 1992
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 23
Study: 2227222

Group type: EXPERIMENTAL
Intervention: Gallopamil slow release (100 mg, twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gallopamil immediate release (50 mg, four times daily)
Number of subjects: 15
Study: 337985

Group type: EXPERIMENTAL
Intervention: Oral droperidol
Number of subjects: 87

Group type: COMPARATOR
Intervention: Oral droperidol plus diazepam
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Atropine (given to all patients)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Droperidol syrup
Number of subjects: 87
Study: 31226977

Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 64
Study: 28521109

Group type: EXPERIMENTAL
Intervention: 22,600 ppm fluoride varnish, toothbrush, a 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized prevention advice
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 1248
Study: 25594647

Group type: EXPERIMENTAL
Intervention: Portable warming gown
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard warming procedure
Number of subjects: 94
Study: 23332800

Group type: EXPERIMENTAL
Intervention: yoghurt enriched with 3 g n‐3 LC‐PUFA/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: yoghurt enriched with 0.8 g n‐3 LC‐PUFA/d
Number of subjects: 53

Group type: COMPARATOR
Intervention: control yoghurt
Number of subjects: 53
Study: 21214690

Group type: EXPERIMENTAL
Intervention: Artesunate‐mefloquine paediatric (AS+MEF)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 156
Study: 18053049

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine/sodium deoxycholate preparation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sodium deoxycholate
Number of subjects: 37
Study: 16427861

Group type: EXPERIMENTAL
Intervention: Cold-blood cardioplegia enriched with N-acetylcysteine (50 mg per kilogram of body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold-blood cardioplegia alone
Number of subjects: 30
Study: 12637852

Group type: EXPERIMENTAL
Intervention: prehospital thrombolysis
Number of subjects: 16

Group type: COMPARATOR
Intervention: usual hospital care
Number of subjects: 16
Study: 10697448

Group type: EXPERIMENTAL
Intervention: Exercise group (2 sessions per week for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group (conventional community cares)
Number of subjects: 38
Study: 9126183

Group type: EXPERIMENTAL
Intervention: UP + CB + weekly chlorhexidine rinse (CHX)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: UP + CB + CHX + semi‐annual fluoride varnish (F)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: UP + CB + CHX + F + semi‐annual prophylaxis, including scaling (P)
Number of subjects: 296

Group type: COMPARATOR
Intervention: usual procedures (UP)
Number of subjects: 296

Group type: COMPARATOR
Intervention: usual procedures (UP) + cognitive‐behavioral intervention (CB)
Number of subjects: 296
Study: 8463520

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg tid for 12 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3948897

Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg bolus followed by 2 mg/h continuous infusion for 8 h)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29652169

Group type: EXPERIMENTAL
Intervention: ACLR group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 26820385

Group type: EXPERIMENTAL
Intervention: Home nursing care with the self-care model (4 visits: 2 in the first month, 2 in the next 2 months)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Home nursing care with the self-care model
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 106
Study: 24746282

Group type: EXPERIMENTAL
Intervention: Skin Stretch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split Skin Grafting (SSG)
Number of subjects: 0
Study: 23116382

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle coaching (therapist followed and coached to increase healthy behaviors)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Emotional support (therapist followed and receiving only emotional support)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No therapist follow-up
Number of subjects: 56
Study: 20855696

Group type: EXPERIMENTAL
Intervention: Skin cancer prevention intervention promoting sunless tanning
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (surveys)
Number of subjects: 250
Study: 19001195

Group type: EXPERIMENTAL
Intervention: 3-year multifactorial continued educational and behavioral program
Number of subjects: 3241

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3241
Study: 15737661

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 15765628

Group type: EXPERIMENTAL
Intervention: Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norgestimate 90 microg/day
Number of subjects: 0
Study: 10077716

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 130

Group type: COMPARATOR
Intervention: Simple foot massage
Number of subjects: 130

Group type: COMPARATOR
Intervention: Personal conversation
Number of subjects: 130
Study: 7741138

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 19
Study: 2297462

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6793276

Group type: EXPERIMENTAL
Intervention: Gentamicin-containing bone cement
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Systemically given antibiotics
Number of subjects: 1633
Study: 31591965

Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olfactory neuroimaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocannabinoid system (ECS) involvement
Number of subjects: 0
Study: 29065193

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dependent smokers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occasional smokers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40
Study: 26765470

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine (YIC)
Number of subjects: 10
Study: 24844551

Group type: EXPERIMENTAL
Intervention: Topical cooling with 4°C saline (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mild hypothermic cardiopulmonary bypass (28‐32°C) without topical cooling (Group II)
Number of subjects: 50
Study: 22540524

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Aspirin 75 mg daily alone
Number of subjects: 250
Study: 19595629

Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment (pramipexole)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pre-treatment condition (no dopaminergic treatment)
Number of subjects: 12
Study: 17337337

Group type: EXPERIMENTAL
Intervention: 5 day communication course
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 16261945

Group type: EXPERIMENTAL
Intervention: Sabal-urtica preparation PRO 160/120
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12123338

Group type: EXPERIMENTAL
Intervention: GEP (gemcitabine 1000 mg/m2, epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EP (epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Epirubicin alone (90 mg/m2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GEP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EP
Number of subjects: 27
Study: 9021203

Group type: EXPERIMENTAL
Intervention: 3.375 g of piperacillin-tazobactam intravenously every 6 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4.5 g of piperacillin-tazobactam intravenously every 8 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.1 g of ticarcillin-clavulanate intravenously every 6 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.0 g of ampicillin-sulbactam intravenously every 6 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 12
Study: 8113461

Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ELND with hyperthermic limb perfusion
Number of subjects: 0
Study: 3351705

Group type: EXPERIMENTAL
Intervention: Locally prepared milk‐free formulation (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spray dried commercial cow's milk formula (group B)
Number of subjects: 60
Study: 29319050

Group type: EXPERIMENTAL
Intervention: Sweat Rate
Number of subjects: 136

Group type: COMPARATOR
Intervention: Wet Bulb Globe Temperature (WBGT)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Agreement between Sweat Rate and WBGT
Number of subjects: 136
Study: 26536315

Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Community and partner discouragement regarding the study pill
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Limited acceptability of the pill's attributes
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Concerns about HIV-related stigma
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Trial's ancillary benefits and visit reimbursement
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Negative patient-provider relationships
Number of subjects: 312
Study: 24637965

Group type: EXPERIMENTAL
Intervention: Low-protein experimental formula (EXPL) with 1.65 g of protein/100 kcal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula (CTRL) with 2.7 g of protein/100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-protein experimental formula (EXPL)
Number of subjects: 0